Tirosint Manufacturing, Supply and Shortage History: What Women With Hypothyroidism Need to Know

What Tirosint Is and Why Its Supply Chain Matters

Tirosint is not simply a branded version of a generic tablet. It is a distinct dosage form: levothyroxine sodium dissolved in a soft gelatin capsule containing glycerin, gelatin, and water, with no fillers, dyes, or acacia. That near-excipient-free formulation is precisely why gastroenterologists and endocrinologists reach for it when standard tablets fail, and precisely why a manufacturing disruption hits women with complex GI or autoimmune histories harder than a shortage of generic tablet levothyroxine would.

Women make up roughly 60-70% of autoimmune thyroid disease cases, which means any Tirosint supply problem is, statistically, a women's health problem. For a woman managing Hashimoto thyroiditis alongside celiac disease or post-bariatric anatomy, losing access to her gel-cap formulation is not a minor inconvenience. It can mean weeks of subtherapeutic TSH levels, returning fatigue, hair loss, and, if she is pregnant, real fetal risk.

The Single-Manufacturer Problem

Tirosint and Tirosint-SOL are both manufactured exclusively by IBSA Institut Biochimique SA, a Swiss specialty pharmaceutical company founded in 1945 and headquartered in Lugano. IBSA holds the New Drug Application for both products in the United States. No other company has received FDA approval to manufacture a bioequivalent soft-gel levothyroxine capsule as of 2025. That single-source status means any production interruption, raw material shortage, or regulatory action at one Swiss facility propagates directly to every US pharmacy shelf carrying Tirosint.

Generic tablet levothyroxine, by contrast, is produced by at least six manufacturers including Mylan, Lannett, and Amneal, giving the tablet market a supply buffer that the gel-cap market simply does not have.

How the Gel-Cap Formulation Is Made

Levothyroxine is a narrow-therapeutic-index drug. The FDA requires that levothyroxine products demonstrate bioequivalence within a tighter 90% confidence interval than most drugs (90-111% for AUC and Cmax rather than the standard 80-125%). Manufacturing the gel-cap form requires:

1. Dissolving levothyroxine sodium in a precise ratio of glycerin and purified water
2. Encapsulating that liquid in gelatin shells under controlled temperature and humidity
3. Testing each batch for potency across the full storage period, because levothyroxine degrades when exposed to light, heat, or moisture

The gelatin shell itself requires a pharmaceutical-grade supply chain. Any disruption to gelatin sourcing, glycerin purity, or the encapsulation line can pause production for weeks to months before corrective batches pass FDA release testing.

The History of Tirosint Supply Disruptions in the United States

Early Market Entry and the First Availability Challenges (2013-2016)

IBSA received FDA approval for Tirosint in December 2012. The product entered a market already dominated by brand-name Synthroid and a growing number of generic tablets. Initial rollout was slow. Many pharmacies, particularly independent and smaller chain pharmacies, did not stock it routinely because reimbursement pathways were unclear and prescribing volume was low.

During 2013 and 2014, clinicians reported sporadic availability gaps, especially for less common strengths such as 13 mcg (used in pediatrics and fine-tuning doses in small women) and 137 mcg. These were not formal FDA-declared shortages, but rather distribution bottlenecks as IBSA scaled US supply from its European manufacturing base.

The Vita et al. 2014 publication in Endocrine helped legitimize Tirosint prescribing by showing that patients with malabsorption achieved significantly better TSH normalization on the gel-cap versus standard levothyroxine tablets. That paper drove prescribing volume up, putting additional pressure on a supply chain that was already tight.

The 2019-2020 Disruption

The most widely reported Tirosint shortage in the United States occurred between late 2019 and mid-2020. FDA drug shortage records documented a shortage of levothyroxine products during this period, with gel-cap forms particularly affected. IBSA cited manufacturing capacity constraints and increased demand.

Clinicians in thyroid-focused Facebook groups and professional forums reported that 88-mcg and 100-mcg gel caps were the hardest strengths to find, likely because these are the most commonly prescribed mid-range doses for adult women. Some patients went weeks without their usual formulation.

2022-2023 Intermittent Availability

A second wave of intermittent shortages emerged in late 2022 and continued through parts of 2023. Supply chain disruptions affecting gelatin, pharmaceutical-grade glycerin, and global shipping logistics all contributed. The FDA's official drug shortage database listed levothyroxine sodium gel capsules as intermittently affected during this window. Patients in online hypothyroidism communities, including those moderated by the American Thyroid Association's patient advocacy arm, documented difficulty obtaining specific strengths for periods of four to twelve weeks.

Where Things Stand in 2025

As of early 2025, Tirosint and Tirosint-SOL are commercially available in the United States but remain vulnerable to the same single-source risk that has caused prior disruptions. The FDA drug shortage database should be your first check if your pharmacy tells you stock is unavailable. IBSA has not announced capacity expansions or a US-based manufacturing partnership as of this writing.

How Tirosint Works: Mechanism and Why It Matters for Women

Levothyroxine is synthetic thyroxine (T4), the same molecule your thyroid gland produces. Once absorbed, T4 is converted peripherally, primarily in the liver and kidneys, to triiodothyronine (T3), the metabolically active form. T3 then binds nuclear thyroid hormone receptors to regulate gene expression governing metabolism, heart rate, bone turnover, menstrual cycle regularity, and CNS function.

Why the Gel-Cap Formulation Achieves Better Absorption

Standard levothyroxine tablets depend on gastric acid to dissolve the active ingredient before it can be absorbed in the proximal small intestine. Women with:

• Hashimoto thyroiditis and associated autoimmune gastritis
• Celiac disease (which disproportionately affects women at a 2:1 female-to-male ratio)
• Post-bariatric anatomy (Roux-en-Y gastric bypass, sleeve gastrectomy)
• Proton-pump inhibitor use
• H. Pylori-associated hypochlorhydria

...often absorb tablet levothyroxine poorly because the tablet's dissolution depends on acid and an intact proximal GI tract. The Tirosint gel cap delivers levothyroxine already in solution, bypassing the dissolution step. The Vita et al. Trial (Endocrine, 2014) enrolled 57 patients with chronic gastritis or H. Pylori infection on stable tablet doses and switched them to equivalent-dose gel caps. Mean TSH fell from 4.07 mIU/L on tablets to 1.82 mIU/L on gel caps without any dose change, a clinically meaningful difference that confirmed the absorption advantage in this population.

Sex-Specific Pharmacokinetics

Women metabolize levothyroxine differently across the life cycle, and this is not always accounted for in prescribing. Key points:

• Body size and volume of distribution. Women, on average, have lower lean body mass than men of the same weight, which affects the weight-based dosing calculation of approximately 1.6 mcg/kg/day. Your dose should be calculated against lean body mass, not total weight, particularly if your BMI is above 30.
• Estrogen interactions. Oral estrogen increases thyroid-binding globulin (TBG), which binds free T4 and can render a previously adequate dose insufficient. Women starting oral contraceptives or oral menopausal hormone therapy often need a levothyroxine dose increase. Transdermal estrogen has a smaller effect on TBG and may not require the same adjustment.
• Absorption timing. Calcium carbonate, iron supplements, and antacids all reduce levothyroxine absorption. Women are prescribed these agents at higher rates than men (calcium for bone protection, iron for premenopausal blood loss), so the interaction is clinically more frequent in women.

Tirosint Across Life Stages

Reproductive Years and Trying to Conceive

If you have hypothyroidism and are trying to conceive, ACOG recommends a preconception TSH target of <2.5 mIU/L. Tirosint is a reasonable choice for women who have documented malabsorption issues affecting tablet levothyroxine stability, since conception is more likely when TSH is reliably in range. If you switch formulations while trying to conceive, recheck TSH in four to six weeks.

Pregnancy

Pregnancy is the single most important time to have stable thyroid hormone levels. Fetal thyroid function is not autonomous until approximately 20 weeks gestation, meaning the fetus depends on maternal T4 for the first half of pregnancy. Untreated or under-treated maternal hypothyroidism is associated with impaired fetal neurodevelopment and increased pregnancy loss risk.

Levothyroxine requirements increase by 25-50% during pregnancy, often as early as four to six weeks gestation. For a woman on 100 mcg Tirosint, this may mean needing 125 mcg or 137 mcg by the end of the first trimester. Some clinicians instruct their patients to add two extra doses per week the moment pregnancy is confirmed rather than waiting for a lab draw.

Tirosint's gel-cap formulation has no specific teratogenic concern. Levothyroxine is a category A drug and is considered safe throughout pregnancy. The priority is adequate replacement, not avoidance.

A practical framework for pregnant women on Tirosint during a shortage:

If your Tirosint strength is unavailable:

1. Ask your clinician to check whether an adjacent strength (e.g., splitting 200-mcg capsules or combining smaller strengths) is in stock.
2. Tirosint-SOL liquid ampules may be available when gel caps are not, since they are produced and shipped separately.
3. Switching to brand-name Synthroid (not generic tablet) is the most pharmacokinetically predictable tablet alternative. Recheck TSH at four weeks after any formulation change.
4. Never just stop levothyroxine while pregnant. Untreated hypothyroidism carries more fetal risk than any formulation switch.

Postpartum and Lactation

Levothyroxine transfers into breast milk in very small amounts. Breast milk T4 levels in treated hypothyroid mothers are not higher than those in euthyroid mothers, and the amount transferred is considered insufficient to cause thyroid suppression or harm in the nursing infant. Tirosint is compatible with breastfeeding.

Postpartum thyroiditis affects approximately 5-10% of women in the first year after delivery. It can cause transient hyperthyroidism followed by hypothyroidism. Some women with postpartum thyroiditis require short-term levothyroxine that may be discontinued after six to twelve months. If you are started on Tirosint during postpartum thyroiditis, the plan for reevaluation and possible discontinuation should be explicit from the beginning.

Perimenopause and Menopause

Perimenopause and menopause bring two intersecting challenges for women on levothyroxine.

First, fluctuating estrogen levels during perimenopause change TBG concentrations unpredictably, which can cause TSH to swing even on a stable levothyroxine dose. Women in perimenopause may need more frequent TSH monitoring, approximately every three to six months rather than annually.

Second, if you start menopausal hormone therapy, the route of administration matters. Oral estradiol or conjugated equine estrogen raises TBG, which can reduce free T4 and require a Tirosint dose increase. Transdermal estradiol (patch, gel, or spray) has a much smaller effect on TBG because it bypasses first-pass hepatic metabolism. If you have both hypothyroidism and symptomatic menopause, your clinician should discuss route of estrogen delivery in the context of your thyroid medication needs.

Who Tirosint Is Right For, and Who May Not Need It

Strong Candidates

• Women with confirmed malabsorption causing persistently elevated TSH despite adequate tablet doses and good adherence
• Post-bariatric surgery patients (particularly Roux-en-Y, which dramatically alters proximal gut anatomy)
• Women with celiac disease who are gluten-free but still absorbing tablets poorly
• Women with autoimmune gastritis or H. Pylori-associated achlorhydria
• Women with lactose intolerance who react to the lactose filler in most generic levothyroxine tablets
• Women with multiple drug sensitivities who cannot tolerate any tablet excipient

Women Who May Not Benefit Enough to Justify the Risk of Single-Source Supply

• Women with well-controlled TSH on generic tablet levothyroxine and no GI comorbidities
• Women whose TSH is elevated due to non-adherence or timing errors rather than true malabsorption
• Women in regions where Tirosint is intermittently unavailable and where formulation switches would themselves cause TSH instability

The decision to prescribe Tirosint should be documented with a clear clinical rationale, especially in pregnant women, because a shortage-forced switch during pregnancy carries its own risks.

What to Do If Tirosint Is Out of Stock

Immediate Steps

1. Check FDA's current drug shortage database to confirm whether this is a national shortage or a local stocking issue.
2. Call multiple pharmacies. Specialty and compounding pharmacies sometimes maintain buffer stock.
3. Ask if Tirosint-SOL liquid ampules in your dose are available. The SOL formulation uses a different packaging and production line, so its availability does not always track the gel-cap shortage.
4. Contact your clinician before making any switch. Do not substitute generic tablet levothyroxine on your own without a TSH recheck planned at four weeks.

Switching Formulations Safely

The American Thyroid Association guidelines recommend that any change in levothyroxine brand or formulation be followed by a TSH recheck at four to six weeks. For pregnant women, that window shortens to four weeks. For women in the first trimester, some endocrinologists check TSH at two to three weeks after a forced switch given the time-sensitivity of fetal neurodevelopment.

Brand-name Synthroid is the closest pharmacokinetically predictable tablet alternative to Tirosint for women who need to switch under shortage conditions. Generic levothyroxine tablets are bioequivalent but excipient composition varies by manufacturer, which can matter for women with the sensitivity profiles that drove the Tirosint prescription in the first place.

Pregnancy and Lactation Safety: Required Reference Section

Pregnancy category: Levothyroxine is FDA pregnancy category A. It is not a teratogen. Adequate replacement is mandatory for fetal wellbeing.

Human pregnancy data: Observational studies and registry data consistently show that untreated or under-treated maternal hypothyroidism causes greater harm than any formulation-related risk. The ACOG Practice Bulletin on Thyroid Disease in Pregnancy explicitly states: "Overt hypothyroidism should be treated in pregnant women."

Dose escalation in pregnancy: Dose requirements rise by 25-50%. Some clinicians use the strategy of immediately adding two extra doses per week upon a confirmed positive pregnancy test, then titrating based on labs.

Lactation: Levothyroxine passes into breast milk in clinically negligible quantities. The National Institutes of Health LactMed database classifies levothyroxine as compatible with breastfeeding. No dose adjustment is needed for nursing mothers beyond standard postpartum TSH monitoring.

Contraception: Levothyroxine is not a teratogen and does not require contraception as a prescribing condition. However, women with poorly controlled hypothyroidism have higher rates of anovulation and menstrual irregularity, so achieving TSH control may itself improve fertility and make unintended pregnancy more likely. If pregnancy is not desired, effective contraception is worth discussing in parallel with thyroid optimization.

Evidence Gap: What We Still Do Not Know

Women have been under-represented in thyroid pharmacology trials. The Vita et al. 2014 study was small (57 patients) and enrolled both men and women without reporting sex-stratified absorption data. We do not have a trial specifically examining Tirosint gel-cap pharmacokinetics in pregnant women, in women on oral versus transdermal estrogen, or in women across the perimenopausal transition. Dosing recommendations for these groups are extrapolated from physiological reasoning and general levothyroxine literature, not from gel-cap-specific trials. This gap is worth naming because it is real, and because it means your clinician may need to monitor you more closely when your hormonal status changes.